The Commission disagreed with this view. The first half of the suspension IP was affected by the COVID-19 pandemic and the VAM shortage. In the second half, the Union industry, while benefitting from the measures, was able to increase its production to fulfil Union demand. While this is a clear sign of recovery, the investigation demonstrated that: (i) Chinese exporting producers have significant spare capacity still available and are already exporting to the EU in significant quantities even with the duties in place, (ii) their prices still undercut the Union prices even with anti-dumping duties included, (iii) the Union market is attractive for the Chinese producers for its price levels and the significant demand, and (iv) the increase in VAM prices is negatively affecting the Union industry cost of production and its profitability. Taking into consideration all of these elements, the Commission concluded that injury, even if it were not to be present, would most likely resume as a result of the suspension.
60 3. LIKELIHOOD OF RESUMPTION OF INJURY, Decision_act (EU) 2022/1397
In forcesince 11 Aug 2022